John L. Marshall, MD: Zolbetuximab is a drug that you probably don’t know the name of, but you’re going to soon. Though you may have heard of claudin 18.2. Now, that’s been in the literature for a ...
Comparing outcomes for early and late drainage of malignant ascites. Background: Black individuals, including African Americans, experience a disproportionate cancer burden and exhibit the lowest ...
A population-based study drew a possible connection between gastrointestinal (GI) symptoms and the multiple sclerosis (MS) prodrome. Patients with multiple sclerosis (MS) endure higher rates of drug ...
Gastrointestinal disorders may affect around 40% of people worldwide, according to one recent study. GI disorders can include several conditions, including celiac disease, gastritis, Crohn's disease, ...
71.4% of MetaXplore™ reports from 4,616 patients identified actionable results 41.9% tested positive for abnormal microbiome markers linked to gastrointestinal health 9.9% tested positive for ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results